• Numerous clinical trials have been conducted in psoriasis, many of which have included general dermatologic or psoriasis-specific patient-reported outcomes (PROs) as study outcome measures.
• In 2009, both the FDA's PRO Guidance 4 and ISPOR Good Research Practices Task Force 5 provided recommendations on how PROs should be created to support claims in approved medical product labeling.
• Commonly used PROs in psoriasis trials include the Psoriasis Quality of Life Questionnaire (PQOL-12), Dermatology Life Quality Index (DLQI), Skindex, Psoriasis Disability Index (PDI), Psoriasis Life Stress Inventory (PLSI), and Psoriasis Symptom Inventory (PSI).
• This study assessed how well the development and validation process of these PROs align with the 2009 FDA PRO Guidance criteria.
BACKGROUND
• The development and validation studies of six PROs were evaluated against the FDA's PRO Guidance's criteria for content validity and psychometric testing.
• PROs were identified from a PubMed literature search. A total of 48 studies which evaluated content validity or psychometrics were identified. An additional 9 studies were identified from reference lists of the articles and a general search. The PROs identified were cross-referenced in clinicaltrials.gov to assess their use in the clinical trial setting.
• Data from the identified articles were evaluated for fulfillment of the following criteria: literature review, clinician input, concept elicitation with patients, achievement of saturation, content validity of items assessed with patients, recall period validated with patients, response options validated with patients, item tracking matrix, conceptual framework, internal consistency reliability, test-retest reliability, convergent validity, known groups validity, and ability to detect change.
• Each criteria was assessed by a rating: "meets guideline", "partially meets guideline", "significant concerns on not meeting guideline", and "no evidence". 
METHODS

REFERENCES
• The PQOL-12 6, 7, 8 is a self-administered 12-item, psoriasis-specific PRO with a recall period of the past month. It assesses a broad range of issues including emotional issues, body image and social acceptability issues, overall psychosocial well-being, day-to-day activities, and day-to-day physical impact organized.
• The DLQI 9, 10, 11, 12 is a self-administered 10-item PRO, applicable to patients with any skin disease with a recall period of the last week. It assesses symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment-related distress as related to the patient's skin condition.
• The Skindex-29 13,14,15 is a self-administered 29-item PRO, applicable to patients with any skin disease with a recall period of the last four weeks. It assesses emotions, symptoms, and functioning as related to the patient's skin condition.
• The PDI 16, 17, 18 is a self-administered 15-item, psoriasis-specific PRO with a recall period of the last four weeks. It assesses daily activities, work or school, personal relationships, leisure, and treatment as related to the patient's psoriasis.
• The PLSI 19, 20 is a self-administered 15-item, psoriasis-specific PRO with a recall period of the past month. It assesses psoriasis-related stress including the psychosocial impact of psoriasis. • PROs and studies were identified from publically available sources. Any relevant materials that are not currently available for review were not included.
RESULTS
Guideline
• Authors of articles may have not included all the details pertaining to instrument development as assessed in this gap analysis. Published articles may not have included details on a literature review; however, the background sections of most articles provided a brief summary. Conceptual frameworks are also rarely published in detail.
• This analysis did not include a review of the dimensionality and scoring of the PROs.
• This review does not apply to regulatory guidelines outside the US.
LIMITATIONS
• The only psoriasis-specific PRO measure that has met the recommendations of the FDA's PRO Guidance is the Psoriasis Symptom Inventory. However, this PRO focuses solely on symptoms.
• Although the gaps for meeting the FDA's Guidance criteria for these PROs are variable, the PROs reviewed have undergone somewhat extensive psychometric evaluations.
• Based on this review, additional qualitative and quantitative research is needed to eliminate the identified gaps before most of these PROs could fulfill the FDA guidance for inclusion as a measure for a PRO label claim.
CONCLUSIONS
• The PSI 21,22,23 is a self-administered 8-item psoriasis-specific PRO with a recall period of the last 7 days. It assess itching, redness, scaling, burning, stinging, cracking, flaking, and pain.
• Table 1 presents the gap analysis of each PRO as assessed according to the 2009 FDA PRO Guidance. 2, 3 • For example of "fully meets guideline," the developers of the PSI described the concept elicitation phase in detail and the various steps in how the qualitative data were analyzed.
• For an example of "significant concerns for this guideline," the content validity for the PDI did not detail input from psoriasis patients. Further, in one study, the data were collated for adolescent and adult patients (aged 14-73 years). 17 • Only the PSI met all the criteria as specified by the FDA's Guidance Report.
• Internal consistency reliability of all six PROs has been well documented.
• Four of the PROs did not have evidence of saturation in concepts during concept elicitation research or a published conceptual framework.
